Clinical trials: Chemoradiotherapy
Rectal Neoplasms
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma
The investigators propose to conduct a randomised study on cT2, cT3a-b tumours less than 5 cm using two different techniques of radiotherapy boost following neoadjuvant chemoradiotherapy (nCRT) (CAP45): EBRT (9 Gy/5 fractions) or…
- Trial name
- OPERA (NCT02505750)
- Testing
- 3D conformal EBRT, Contact X-ray brachytherapy 50 kV, Capecitabine
- Where
- 18 sites in France, Switzerland and 1 more
- Volunteers
- 148 people
- Sponsor
- Centre Antoine Lacassagne
Rectal Neoplasms
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer
Standard treatment for locally advanced cancer of the rectum is preoperative chemoradiotherapy with 5-Fluorouracil (5-FU) plus 4 cycles of postoperative chemotherapy with 5-FU.
- Trial name
- NCT00349076
- Testing
- 5-FU and oxaliplatin, 5-FU
- Where
- 89 sites in Germany
- Volunteers
- 1,256 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Head and Neck Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004089
- Testing
- filgrastim, fluorouracil, hydroxyurea
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma
A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of Sintilimab for Consolidation Therapy After Radical Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04514835
- Testing
- Cisplatin+Capecitabine+Sintilimab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Pancreatic Cancer
GI-4000 With Adoptive Transfer in Pancreatic Cancer
The purpose of this study is to determine if it is safe to add multiple immunotherapies to standard chemotherapy and radiation for treating pancreatic cancer tumors that cannot be completely removed by surgery. 1.
- Trial name
- NCT00837135
- Testing
- Screening, GI-4000 Vaccine, GI-4000 Vaccine + Activated T Cells
- Sponsor
- University of Pennsylvania
Nasopharyngeal Carcinoma
OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy
This is a lead-in dose escalation study to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD), and recommended Phase II dose of OPB-51602 administered on a weekly basis in subjects with advanced…
- Trial name
- NCT02058017
- Testing
- OPB-51602
- Where
- Singapore
- Volunteers
- 9 people
- Sponsor
- National University Hospital, Singapore
Head and Neck Cancer
Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)
The aim of this clinical research project is to validate the prognostic impact of potential biomarkers on loco-regional control of locally advanced head and neck cancer after definitive or adjuvant radiochemotherapy.
- Trial name
- HNprädBio (NCT02059668)
- Testing
- Biomarker analyses head & neck cancer tissue, blood specimen
- Where
- 10 sites in Germany
- Volunteers
- 588 people
- Sponsor
- Technische Universität Dresden
Oesophageal Adenocarcinoma, Tumor Microenvironment
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.
- Trial name
- MEMENTO (NCT06687876)
- Testing
- Metformin
- Where
- 2 sites in Netherlands
- Volunteers
- 14 people
- Sponsor
- Amsterdam UMC, location VUmc
Rectal Cancer
Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX
In this phase I trial neoadjuvant CCRT combining IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and BV-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens is planned for 15 locally advanced…
- Trial name
- NCT01395667
- Testing
- CCRT
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- National Taiwan University Hospital
Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy.
- Conditions
- Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT02349867
- Testing
- Gemcitabine, Sorafenib, Vorinostat
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Virginia Commonwealth University
Esophageal Squamous Cell Carcinoma
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the efficacy and safety of apatinib plus concurrent neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
- Trial name
- NCT03857763
- Testing
- Apatinib,Paclitaxel,Cisplatin,RT
- Volunteers
- 40 people
- Sponsor
- Hebei Medical University Fourth Hospital
Lung Adenocarcinoma
Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma
This prospective phase II study is to determine the efficacy and safety of bevacizumab maintenance therapy after concurrent chemoradiotherapy in locally advanced lung adenocarcinoma
- Trial name
- NCT03904563
- Testing
- Bevacizumab, chest radiation, concurrent chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
Lung Cancer (NSCLC)
Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLC
This is a prospective, randomized phase II study evaluating concurrent chemoradiotherapy combined with full-course immunotherapy or consolidative immunotherapy in patients with unresectable, locally advanced non-small cell lung…
- Trial name
- NCT07874464
- Testing
- Induction chemoimmunotherapy, radiotherapy, Concurrent Chemotherapy
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Sun Yat-sen University
Cancer of the Head and Neck, Radiotherapy
Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis
This study will evaluate the role of cyclooxygenase pathways in radiation-induced and chemoradiation-induced mucositis.
- Trial name
- NCT01252498
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Vermont
Locally Advanced Non-Small Cell Lung Cancer, Chemoradiotherapy
Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy
For patients with irresectable locally advanced non-small cell lung cancer (NSCLC) (e.g. multilevel or bulky N2 disease or presence of N3 lymph node metastases), current guidelines recommend treatment with chemoradiotherapy (CRT)…
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Chemoradiotherapy, Cavitation Lung, Surgery
- Trial name
- UPLAN-I (NCT05620199)
- Testing
- Upfront resection
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Glioblastoma Multiforme
Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients
The aim of this study is to establish FET-PET as an additional therapy assessment parameter in patients diagnosed with a glioblastoma multiforme receiving radiochemotherapy and adjuvant chemotherapy after previous resection or…
- Trial name
- NCT01089868
- Where
- 3 sites in Germany
- Volunteers
- 79 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Rectal Cancer
Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy
With the possibility of pathological complete response in surgical specimens, some authors have proposed non-operative management of the patient group, when re-staged after neoadjuvant treatment, have complete clinical response.
- Trial name
- NCT02052921
- Testing
- Rectal resection, Observation
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Esophageal Squamous Cell Carcinoma
Identification of Breath Biomarkers in Esophageal Cancer
Neoadjuvant chemoradiotherapy (CRT) followed by surgery or definitive CRT is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC), but the clinical outcomes are not satisfactory.
- Trial name
- EC-CRT-005 (NCT05557955)
- Testing
- Breathing test
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Mian XI
Organoids, Rectal Cancer
Organoids in Predicting Chemoradiation Sensitivity on Rectal Cancer
Patients with locally advanced rectal cancer will receive biopsy before the standard treatment of neoadjuvant chemoradiation. The investigators are going to establish organoids model from the pre-treatment biopsies and expose…
- Conditions
- Organoids, Rectal Cancer, Chemoradiation
- Trial name
- NCT03577808
- Testing
- Biopsy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhen Zhang
Esophageal Squamous Cell Carcinoma
ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma
To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.
- Trial name
- NCT05426850
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.